Get the Stockscreener App
9.98
3.57%
-0.37
Fennec Pharmaceuticals Inc stock is traded at $9.98, with a volume of 129.97K.
It is down -3.57% in the last 24 hours and down -5.40% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$10.35
Open:
$10.2
24h Volume:
129.97K
Relative Volume:
1.00
Market Cap:
$349.97M
Revenue:
$51.00M
Net Income/Loss:
$-8.73M
P/E Ratio:
-33.69
EPS:
-0.2962
Net Cash Flow:
$-7.75M
1W Performance:
-6.82%
1M Performance:
-5.40%
6M Performance:
+58.41%
1Y Performance:
+15.51%
1-Day Range:
$9.87
$10.35
1-Week Range:
$9.87
$10.83
52-Week Range:
$5.65
$13.25
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
9.98 | 349.97M | 51.00M | -8.73M | -7.75M | -0.2962 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Initiated | B. Riley Securities | Buy |
| Jan-09-26 | Initiated | Piper Sandler | Overweight |
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
View All
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
Terry L. Evans Purchases 2,326 Shares Through Fennec Pharmaceuticals ESPP - Kalkine Media
Form 4 FENNEC PHARMACEUTICALS INC.: Jeffrey S. Hackman (Director, CEO) For: 12 October - Investing.com Canada
TRex Bio Files for Nasdaq IPO - Yahoo! Finance Canada
Award shares leave restriction as Fennec Pharmaceuticals (FENC) CFO acquires 1,703 shares. - stocktitan.net
Medical chief acquires 168 awarded shares at Fennec Pharmaceuticals (FENC), holding 9,687 directly. - stocktitan.net
Commercial chief acquires 168 shares released from restriction at Fennec Pharmaceuticals (FENC). - stocktitan.net
1,159 award shares released; Fennec Pharmaceuticals (FENC) CEO directly holds 67,461 shares afterward. - stocktitan.net
After a 156-share award release, Fennec (FENC) strategy chief holds 24,800 shares. - stocktitan.net
FENC 8-K FilingsFennec Pharmaceuticals Inc. SEC 8-K - stocktitan.net
Fennec Pharmaceuticals (FENC) director exercises options, then sells matching shares - Stock Titan
Director at Fennec Pharmaceuticals (NASDAQ: FENC) plans to sell 15,545 shares - Stock Titan
Fennec Pharmaceuticals (NasdaqCM:FENC) Stock Forecast & Analyst Predictions - Simply Wall Street
Why Fennec Pharmaceuticals Inc stock plummeted yesterday - Wealth Awesome
(FENC) Risk Channels and Responsive Allocation - Stock Traders Daily
Fennec Pharmaceuticals Stock Price Forecast. Should You Buy FRX.TO? - StockInvest.us
What's Going On With Fennec Pharmaceuticals Inc Stock Thursday? - Wealth Awesome
Fennec Pharmaceuticals Insider Rosty Raykov Reports Share Vesting and Sale - kalkinemedia.com
Former Fennec (NASDAQ: FENC) director lines up $121K stock sale - Stock Titan
Former Fennec Pharma (NASDAQ: FENC) director sells 10,000 shares under 10b5-1 plan - Stock Titan
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Fennec CCO receives 168 shares at zero cost - Stock Titan
Fennec Pharma CEO gains 1,159-share award - Stock Titan
Fennec Pharma (NASDAQ: FENC) officer to sell 12,000 shares - Stock Titan
156 previously restricted Fennec Pharma (FENC) shares are released to the chief strategy officer at a stated $0.00 per share. - Stock Titan
Fennec (NASDAQ: FENC) CMO sells 12,000 vested shares in an August 31 trade not tied to a preset Rule 10b5-1 plan. - Stock Titan
CFO boosts stake at Fennec Pharmaceuticals (FENC) as 1,703 previously restricted shares are released to him - Stock Titan
Trade Alert: Chief Financial Officer Of Fennec Pharmaceuticals Robert Andrade Has Sold Stock - webull.com
Trade Alert: Chief Financial Officer Of Fennec Pharmaceuticals Robert Andrade Has Sold Stock - simplywall.st
Fennec Pharma (NASDAQ: FENC) CFO sells 75K shares in plan trade - Stock Titan
Fennec Pharma (NASDAQ: FENC) officer to sell 75,000 shares - Stock Titan
What's Going On With Fennec Pharmaceuticals Inc Stock Thursday? - Wealth Awesome
Fennec Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:FENC - TradingView
Fennec (FENC) Results Review: Reported EPS Tops Expectations in the Latest Reading; Share Response: The Share Price Sheds 4.63% at the CloseEPS Estimate Trend - vinanet.vn
Fennec (FENC) Results Check: Profit Per Share Clears Its Benchmark on the Day; Investor Response - vinanet.vn
Fennec (FENC) Technical Check: Adds 0.51% to Close at $11.89 at the Close; Current Setup: the Supplied Trading Band Runs From $11.30 to $12.48Throwback Trade - vinanet.vn
Jessica Vargas Appointed Vice President of Human Resources at Fennec Pharmaceuticals - hrtoday.in
(FENC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Fennec Pharmaceuticals (FENC): Southpoint group files 13G/A showing 0% ownership - Stock Titan
Fennec Pharmaceuticals (FENC) Gets a Buy from Maxim Group - The Globe and Mail
Solas Capital Management (FENC) reports 1.89M Fennec shares, a 5.4% ownership stake - Stock Titan
Results: Fennec Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Moomoo
Results: Fennec Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Results: Fennec Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views - Yahoo Finance
Fennec Pharmaceuticals Announces Q2 2026 Net Income and Revenue Growth - Kalkine Media
Fennec Pharmaceuticals (FENC) Stock Jumps As Profitability Raises A Bigger Question - webull.com
Fennec Pharmaceuticals (FENC) gains 9.6% stakeholder via Rosalind Advisors - Stock Titan
Fennec Pharmaceuticals (FENC) Gets a Buy from Wedbush - The Globe and Mail
Why Fennec Pharmaceuticals Inc stock plummeted yesterday - Wealth Awesome
What's Going On With Fennec Pharmaceuticals Inc Stock Thursday? - Wealth Awesome
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fennec Pharmaceuticals Inc Stock (FENC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MARCO BRUGHERA | Director |
Sep 15 '26 |
Proposed Sale |
10.30 |
15,545 |
160,070 |
0 |
| Brughera Marco Maria | Director |
Sep 15 '26 |
Sale |
10.29 |
15,545 |
159,958 |
0 |
| ROSTISLAV RAYKOV | Former Director |
Sep 01 '26 |
Proposed Sale |
12.12 |
10,000 |
121,177 |
0 |
| Raykov Rosty | Former Director |
Sep 01 '26 |
Sale |
12.11 |
10,000 |
121,100 |
124,411 |
| PIERRE S SAYAD | Officer |
Aug 31 '26 |
Proposed Sale |
12.18 |
12,000 |
146,170 |
0 |
| Sayad Pierre Sargis | Chief Medical Officer |
Aug 31 '26 |
Sale |
12.18 |
12,000 |
146,160 |
9,519 |
| Andrade Robert | CHIEF FINANCIAL OFFICER |
Aug 28 '26 |
Option Exercise |
5.10 |
21,928 |
111,833 |
239,603 |
| ROBERT ANDRADE | Officer |
Aug 27 '26 |
Proposed Sale |
11.79 |
75,000 |
883,898 |
0 |
| Andrade Robert | CHIEF FINANCIAL OFFICER |
Aug 27 '26 |
Sale |
11.78 |
75,000 |
883,500 |
217,675 |
| ROSTISLAV RAYKOV | Former Director |
Aug 03 '26 |
Proposed Sale |
9.58 |
10,000 |
95,835 |
0 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):